---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-021032"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:41:01.984338+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports durable 30.0-month median OS from VERSATILE-002 in HPV16+ HNSCC

## Summary
- Median overall survival (mOS) steady at 30.0 months with ~4.5 months additional follow-up; lower 95% CI increased to 23.9 months.
- Median PFS: 6.3 months; ORR: 35.8%; disease control rate: 77.4%; median DoR: 21.8 months.
- VERSATILE-003 is the only ongoing Phase 3 trial specifically addressing 1L r/m HPV16-positive HNSCC.
- Data presented at ASCO 2025; no new safety signals; 22 of 53 patients still being followed.

## SEC filing metadata
- accession: 0001140361-25-021032
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125021032/0001140361-25-021032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125021032/ef20050049_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-021032
- JSON: https://secwatch.observer/filing/0001140361-25-021032.json
- Plain text: https://secwatch.observer/filing/0001140361-25-021032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.